Heckler and colleagues investigated the impact of CDK4/6 inhibitors on activated CD8+ T cells of breast cancer patients and observed that CDK4/6 inhibition resulted in an increased frequency of memory CD8+ T cell precursors (Heckler et al., 2021). Here, CDK4 is linked to breast carcinoma.